Lehigh Valley Health Network

LVHN Scholarly Works

Patient Care Services / Nursing

Boosting Education While Boosting the Immune System

Mandy Hendricks RN MSN OCN

Lehigh Valley Health Network, Mandy. Hendricks@lvhn.org

Cathy Cerami RN, BSN, OCN

Lehigh Valley Health Network, cathy.cerami@lvhn.org

Follow this and additional works at: https://scholarlyworks.lvhn.org/patient-care-services-nursing



Let us know how access to this document benefits you

Published In/Presented At

Hendricks, M., & Cerami, C. (2016, April 27). *Boosting Education While Boosting the Immune System.*Poster presented at: Oncology Nursing Society 41st Annual Congress, San Antonio, TX.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Boosting Education While Boosting the Immune System

Mandy Hendricks, RN, MSN, AOCNS and Cathy Cerami, RN, BSN, OCN

Lehigh Valley Health Network, Allentown, Pennsylvania




To educate staff and patients on immune-mediated adverse event.

Significance & Background

- Since 2011 the Food and Drug Administration (FDA) has released over 80 drug approvals and/or new indications for Cancer.
- This number is expected to rise as science, technology and therapeutics advance with a more personalized approach to Cancer Care.
- In 2014, all 10 of newly FDA approved drugs worked by attacking the cancer on the molecular level.


Mechanism of Action



From: Programmed Cell Death-1 (PD-1) Pathway Checkpoint Inhibition: Immunooncology for Advanced Melanoma, 2011.

Background

- Immune-mediated adverse reactions are common in patients treated with immunotherapies.
- Since 2011, Lehigh Valley Health Network has opened more than 20 clinical trials including immunotherapies.
- Combined with approval of ipilumumab in 2011, and pembrolizumab and nivolumab in 2014, the number of patients receiving immunotherapy has increased.




LVHN Doses of Immunotherapy			
Year	CTLA-4 Blocking Antibody	PD-1 Blocking Antibody	Total Doses
2011	57	0	57
2012	21	0	21
2013	35	22	57
2014	58	62	120
2015	78	493	571
2016*	31	249	280
TOTAL DOSES	280	826	1106
* as of 3/28/16			

Interventions


- Inpatient and outpatient nurses identified the topic of immunotherapy and adverse events for education during a learning needs assessment
 - Oncology nurse leaders provided in-services to staff specific to the drugs with a large concentration on immune-mediated adverse reactions.

In-Services



- The Lehigh Valley Health Network (LVHN) Cancer Program Patient Education also identified a need for patient education material.
 - A patient education book was developed to provide unique information related to immunotherapy, specifically how to recognize immunemediated adverse reactions.

Excerpt from Patient Education



Evaluation

- Written and verbal feedback of staff reported an increase in knowledge of immunotherapies and their adverse events following the in-services.
- Patients are reporting signs and symptoms of immune-mediated adverse reactions leading to direct hospital admission for prompt management with corticosteroids.

Discussion

- Innovative strategies to educate staff and patients are needed to provide quality care to a growing population of patients receiving immunotherapy.
- The adverse events of immunotherapy are common and much different than chemotherapy or radiation side effects.
- To maintain patient safety, it is imperative for nurses to recognize the symptoms.
- Oncology nurse leaders continue to provide staff education and inservices as needed.

© 2016 Lehigh Valley Health Network

A PASSION FOR BETTER MEDICINE

610-402-CARE LVHN.org

